AKT1 and breast carcinoma: Inhibiting VEGFR-2 tyrosine kinase activity and the downstream signaling pathways including MAPK (Mitogen-activated protein kinase) and PI3K (Phosphatidylinositide 3-kinases)/Akt, ellagic acid decreases MDA-MB-231 breast cancer xenograft growth and p-VEGFR-2 expression.